Skip to Main Content
Breast, Phase II

A Single-Arm, Phase II Study of Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer: The SAPPHO Study

What is the purpose of this trial?

The purpose of this study is to test the safety and effectiveness of a sequence of drugs (a Taxane plus Trastuzumab plus Pertuzumab followed by Trastuzumab Deruxtecan, followed by Tucatinib plus Ado-Trastuzumab Emtansine (T-DM1), followed by Trastuzumab plus Pertuzumab plus Tucatinib) in HER2+ Breast Cancer. The study will help investigators understand whether first intensifying therapy for a specific period and then stopping treatment is safe and effective for participants.

The names of the study drugs involved in this study are:

  • Paclitaxel (a type of anti-microtubule agent)
  • Docetaxel (a type of anti-microtubule agent)
  • Nab-Paclitaxel (a type of anti-microtubule agent)
  • Trastuzumab (a type of IgG1 kappa monoclonal antibody)
  • Pertuzumab (a type of monoclonal antibody)
  • Trastuzumab Deruxtecan (a type of HER2-directed antibody drug conjugate)
  • Tucatinib (Tyrosine Kinase HER2 Inhibitor)
  • Ado-trastuzumab emtansine or T-DM1 (a type of HER2-targeted antibody-drug conjugate)

Contact Information

For more information about this study, including how to volunteer, contact Carl Brown

Help Us Discover!

You can help our team find trials you might be eligible for by creating a volunteer profile in MyChart. To get started, create a volunteer profile, or contact helpusdiscover@yale.edu, or call 877.978.8343 for more information.

  • Last Updated
    11/05/2025
  • Study HIC
    #2000039526